Core Insights - AstraZeneca showcased its commitment to China at the 8th China International Import Expo, emphasizing its expanded production plans and sustainable development achievements [1] - The company signed a cooperation agreement to invest approximately $136 million to enhance production capacity in Qingdao, focusing on inhalation aerosol products for respiratory diseases [3] - AstraZeneca introduced two new oncology drugs approved in China, addressing the needs of nearly 3.8 million breast cancer patients [4] Group 1 - AstraZeneca has been a consistent participant in the Import Expo for eight consecutive years, highlighting its theme of "Honoring China's Commitment, Creating a Healthy Future" [1] - The Qingdao production facility expansion aims to better meet the treatment needs of asthma and COPD patients, utilizing energy-saving technologies for near-zero carbon operations [3] - The company’s global executive vice president expressed confidence in China's innovation ecosystem and the vision of advancing scientific progress and health [3] Group 2 - The three major production bases in China—Wuxi, Taizhou, and Qingdao—showcased significant progress in low-carbon transformation, with Wuxi achieving 100% renewable energy usage [3] - Taizhou's carbon emissions have been reduced by 97.5% compared to 2015 levels, while the Qingdao facility is expected to achieve near-zero carbon operations upon completion [3] - AstraZeneca's new oncology drugs, including Capecitabine and Dazatuzumab, will enhance treatment options for breast cancer patients in China [4] Group 3 - AstraZeneca has aligned its efforts with the "Healthy China 2030" initiative, introducing 18 innovative treatments over the past seven years across various disease areas [4] - The newly opened global strategic R&D center in Beijing is part of a $2.5 billion investment plan, aimed at accelerating the transformation of innovative results into life-changing medications [4]

Core Insights - AstraZeneca showcased its commitment to expanding production in China at the 8th China International Import Expo, highlighting its latest achievements in sustainable development and innovative drug offerings [1][2] - The company signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone, committing to an additional investment of approximately $136 million to enhance production capacity [1] - The expansion aims to increase the production of inhalation aerosol products to better meet the treatment needs of patients with respiratory diseases such as asthma and COPD [1] Investment and Production Expansion - The Qingdao facility expansion will utilize energy-saving technologies to achieve near-zero carbon operations [1] - AstraZeneca's Wuxi facility has achieved 100% renewable energy usage and is recognized for implementing innovative clean heating solutions, receiving carbon neutrality certification [1] - The Taizhou facility has reduced carbon emissions by 97.5% compared to 2015 levels, with the Qingdao facility expected to achieve similar near-zero carbon operations upon completion [1] Innovative Drug Offerings - At the expo, AstraZeneca presented two newly approved oncology drugs in China: QianKede® (Capecitabine Tablets) and Dazhuoyou® (Darbepoetin Alfa Injection) [2] - The company also showcased innovative therapies for various new disease areas [2]

Core Insights - The eighth China International Import Expo opened in Shanghai on November 5, with AstraZeneca participating for the eighth consecutive year, showcasing its commitment to health in China and announcing an expansion of its production base in Qingdao [2] Group 1: New Drug Launch - AstraZeneca showcased two newly approved oncology drugs, QianKede® (Capecitabine Tablets) and Dazhuoyou® (Injection of Dazibotamab), at the expo, aimed at serving nearly 3.8 million patients in China [3] - Over the past seven years, the company has introduced 18 products in China, covering various therapeutic areas including respiratory, renal, digestive, rare diseases, autoimmune, and oncology [3] - The Beijing Global Strategic R&D Center was inaugurated in October, part of a $2.5 billion investment plan to accelerate the translation of innovative results into clinical drugs [3] Group 2: Production Expansion and Sustainability - On the first day of the expo, AstraZeneca signed an agreement with the Qingdao High-tech Zone Management Committee to invest approximately $136 million to expand its production base in Qingdao, enhancing the capacity for inhalation aerosol products to meet the needs of asthma and COPD patients [5] - The expansion project will incorporate energy-saving technologies with the goal of achieving near-zero carbon operations [5] - The company highlighted its three major bases in Wuxi, Taizhou, and Qingdao, with Wuxi achieving 100% renewable energy usage and carbon neutrality certification, and Taizhou reducing carbon emissions by 97.5% compared to 2015 [5][7]